Ticker: ENLV | --- | --- | --- | |--------------|---------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Life-saving | | | | October 2020 | immunomodulating cell therapies | | Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activ ...

United States Securities and Exchange Commission Washington, D.C. 20549 Title of each class Trading symbol Name of each exchange on which registered Ordinary Shares, par value of NIS 0.40 ENLV Nasdaq Capital Market FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Commission file number 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporati ...

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission file number: 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporation or organization) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) Mr. Shmuel Hess Tel: +972.2.6708072 ...